These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16205731)

  • 1. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen.
    Brazzola P; Duval M; Fournet JC; Gauvin F; Dalle JH; Champagne J; Champagne MA
    Bone Marrow Transplant; 2005 Dec; 36(12):1103-5; author reply 1105. PubMed ID: 16205731
    [No Abstract]   [Full Text] [Related]  

  • 2. Allogeneic stem cell transplantation in a patient with dyskeratosis congenita after conditioning with low-dose cyclophosphamide and anti-thymocyte globulin.
    Ayas M; Al-Musa A; Al-Jefri A; Al-Seraihi A; Al-Mahr M; Rifai S; El-Solh H
    Pediatr Blood Cancer; 2007 Jul; 49(1):103-4. PubMed ID: 16317729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced-intensity conditioning for alternative donor hematopoietic stem cell transplantation in patients with dyskeratosis congenita.
    Nishio N; Takahashi Y; Ohashi H; Doisaki S; Muramatsu H; Hama A; Shimada A; Yagasaki H; Kojima S
    Pediatr Transplant; 2011 Mar; 15(2):161-6. PubMed ID: 21176016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation.
    Nelson AS; Marsh RA; Myers KC; Davies SM; Jodele S; O'Brien TA; Mehta PA
    Biol Blood Marrow Transplant; 2016 May; 22(5):884-8. PubMed ID: 26845033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reduced intensity conditioning regimen of fludarabine, cyclophosphamide, antithymocyte globulin, plus 2 Gy TBI facilitates successful hematopoietic cell engraftment in an adult with dyskeratosis congenita.
    Kharfan-Dabaja MA; Otrock ZK; Bacigalupo A; Mahfouz RA; Geara F; Bazarbachi A
    Bone Marrow Transplant; 2012 Sep; 47(9):1254-5. PubMed ID: 22246089
    [No Abstract]   [Full Text] [Related]  

  • 6. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic hematopoietic stem cell transplantation for dyskeratosis congenita.
    Elmahadi S; Muramatsu H; Kojima S
    Curr Opin Hematol; 2016 Nov; 23(6):501-507. PubMed ID: 27607446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive total lymphoid irradiation-based reconditioning regimens enable engraftment after graft rejection or graft failure in patients treated with allogeneic hematopoietic stem cell transplantation.
    Heinzelmann F; Lang PJ; Ottinger H; Faul C; Bethge W; Handgretinger R; Bamberg M; Belka C
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):523-8. PubMed ID: 17869449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita.
    Fioredda F; Iacobelli S; Korthof ET; Knol C; van Biezen A; Bresters D; Veys P; Yoshimi A; Fagioli F; Mats B; Zecca M; Faraci M; Miano M; Arcuri L; Maschan M; O'Brien T; Diaz MA; Sevilla J; Smith O; Peffault de Latour R; de la Fuente J; Or R; Van Lint MT; Tolar J; Aljurf M; Fisher A; Skorobogatova EV; Diaz de Heredia C; Risitano A; Dalle JH; Sedláček P; Ghavamzadeh A; Dufour C
    Br J Haematol; 2018 Oct; 183(1):110-118. PubMed ID: 29984823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen in infants: experience at a single institution in Mexico.
    Llano OG; Perez JC; Rodriguez OC; Guerra CM; Aguirre HG; Garza JL; Rodriguez-Romo L; Almaguer DG
    Pediatr Hematol Oncol; 2008; 25(1):39-47. PubMed ID: 18231953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year retrospective analysis from the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
    Michallet M; Le QH; Mohty M; Prébet T; Nicolini F; Boiron JM; Esperou H; Attal M; Milpied N; Lioure B; Bordigoni P; Yakoub-Agha I; Bourhis JH; Rio B; Deconinck E; Renaud M; Chir Z; Blaise D
    Exp Hematol; 2008 May; 36(5):535-44. PubMed ID: 18346838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors.
    Conrad R; Remberger M; Cederlund K; Ringdén O; Barkholt L
    Haematologica; 2008 Feb; 93(2):265-72. PubMed ID: 18245651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced intensity conditioning regimen with fludarabine, cyclophosphamide, low dose TBI and alemtuzumab leading to successful unrelated umbilical cord stem cell engraftment and survival in two children with dyskeratosis congenita.
    Brown M; Myers D; Shreve N; Rahmetullah R; Radhi M
    Bone Marrow Transplant; 2016 May; 51(5):744-6. PubMed ID: 26808569
    [No Abstract]   [Full Text] [Related]  

  • 16. Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma.
    de Lavallade H; Cassier PA; Bouabdallah R; El-Cheikh J; Faucher C; Fürst S; Coso D; Sainty D; Arnoulet C; Gastaut JA; Chetaille B; Xerri L; Blaise D; Mohty M
    Br J Haematol; 2008 Sep; 142(5):848-50. PubMed ID: 18631344
    [No Abstract]   [Full Text] [Related]  

  • 17. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
    Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
    Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
    Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo T-cell depletion with myeloablative or reduced-intensity conditioning in pediatric hematopoietic stem cell transplantation.
    Seidel MG; Fritsch G; Matthes-Martin S; Lawitschka A; Lion T; Pötschger U; Rosenmayr A; Fischer G; Gadner H; Peters C
    Haematologica; 2005 Oct; 90(10):1405-14. PubMed ID: 16219578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.